Sentien grabs Series A funds from BIVF and Canada's Portage Biotech

Medford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund (BIVF) and Portage Biotech Inc, a Toronto-based developer of pharmaceutical and biotech products. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.

CanadaNorth AmericaBriefs